Pro- and anti-apoptotic Bcl-2 family members implicated in the glucocorticoids induced apoptosis
1. Introduction
1.1. Glucocorticoids therapeutic effects
Synthetic glucocorticoids (GCs) as effective anti-inflammatory therapeutics are the most widely prescribed drugs in the clinic for the treatment of various conditions including asthma, ulcerative colitis, rheumatoid arthritis and hay fever [1-4]. Glucocorticoids in some cases exert effective anti-neoplastic effects in cancers of blood origin such as acute lymphocytic leukaemia (ALL) as a result of the ability of these hormones to induce cell death in blood cells [1-3]. Resistance to glucocorticoid mediated cell death remains one of the main reasons for inefficient therapy [1] and usually occurs upon prolonged glucocorticoid treatment [2] compromising significantly the success of therapy [3]. The molecular mechanisms mediating glucocorticoid dependent initiation of programmed cell death have been extensively investigated but there are several aspects of these pathways that have not yet been clearly defined. Since understanding of these mechanisms would be beneficial towards improving the glucocorticoids therapeutic efficacy further research exemplifying resistance to glucocrticoid treatment is necessary.
Glucocorticoids (GCs) exert their anti-inflammatory and immunosuppressive effects through either genomic or non-genomic mechanisms. Non-genomic early effects of glucocorticoids are induced in tissues bearing high concentrations of this hormone by interfering with the physicochemical properties of plasma and mitochondrial membranes [4]. In particular, glucocorticoids intercalate into these membranes altering lipid peroxidation and membrane permeability [5]. In addition, non-genomic effects of glucocorticoids include early suppression of the mitogen-activated protein kinase (MAPK) and hence inflammatory signal transduction cascades such as calcium influx, phagocytosis, neutrophil degranulation and cellular adhesion [6, 7, 8, 9, 10, 11]. The non genomic effects of GCs are very important in delivering short-term therapeutic benefits to asthma and rheumatoid arthritis which are diseases characterized by high inflammatory state [12].
2. Mechanisms of GC-mediated cell death
At the molecular level GCs exert their function by interacting with their intracellular GC receptor (GR), which is a hormone responsive transcription factor that modulates gene expression of its target genes [13]. Glucocorticoids activate the cellular death machinery through transcriptional and non-transcriptional pathways by means of either the extrinsic or intrinsic pathway of apoptosis [3, 14, 15, 16].
The extrinsic pathway is induced upon activation of the membrane death receptors such as the tumour necrosis factor (TNF) receptor superfamily, member 6, Fas-Ligand (Fas-L) [17]. The binding of Fas-L leads to the activation of effector caspases (caspases 3, 6 and 7) via the activation of inducer caspases, particularly caspase 8 [18]. Evidence that glucocorticoids are involved in the regulation of the extrinsic pathway of apoptosis has been provided by observations suggesting that glucocorticoids inhibit the induction of Fas-L (but not Fas) signalling in T-cell hybridomas [19, 20]. On the contrary inhibition of the extrinsic pathway using the caspase 8 inhibitor cytokine response modifier A (crmA) in pre-B leukemic cells treated with glucocorticoids indicated that GR does not initiate apoptosis in these cells through the extrinsic pathway [21, 22]. The involvement of the intrinsic pathway, on the other hand, in the glucocorticoid mediated cell death and in particular the regulation of the balance between pro- and anti-apoptotic members of the bcl-2 family has been shown in hepatocytes, small cell lung cancer, primary ALL lymphoblasts and animal systems [23, 24].
The intrinsic pathway of cell death is stimulated in response to intracellular signals, and involves mitochondria releasing pro-apoptotic molecules, formation of the apoptosome and activation of the effector caspases via the initiator caspase 9 [25]. The balance between pro- and anti-apoptotic members of the B cell leukaemia/ lymphoma 2-like (Bcl-2) family plays a crucial role in the execution of apoptosis by glucocorticoids through the intrinsic pathway [18]. In particular, glucocorticoids regulate the expression of various genes involved in the initiation of apoptosis, including the pro-apoptotic Bcl-2 family member BCL2-like 11 (Bim) [22, 26, 27, 28]. Transactivation of Bim results in the activation of the Bcl-2–associated X protein (Bax) and the Bcl2-antagonist/killer 1 (Bak), which mediate the disruption of mitochondrial membrane potential and the release of cytochrome c into the cytosol [29]. Cytochrome c then binds to its adaptor apoptotic protease activating factor (Apaf-1), thereby activating caspase 9 and several effector caspases [30]. Furthermore, mitochondria mediate the generation of reactive oxygen species (ROS), which may potentially have an add-on effect on glucocorticoid-induced apoptosis [31].
In some cases glucocorticoids induce apoptosis by using both the intrinsic and the extrinsic pathways. This is mediated by the cleaved caspase-8 which subsequently leads to activation of the pro-apoptotic member of the Bcl-2 family, Bcl-2 homology 3 (BH3) interacting domain death agonist (Bid) [32]. The C-terminal truncated Bid (t-Bid) activates caspase 9 and the effector caspases 3, 6 and 7 [33]. The intrinsic and extrinsic pathways through which glucocorticoids induce apoptosis in cells responsive to these hormones are illustrated in Figure 1.
Several mechanisms have been proposed to explain the evasion of glucocorticoid mediated apoptosis in resistant cells [34]. These include alterations in the activity of the glucocorticoid receptor [35, 36] either due to changes in GR protein levels, presence of multiple GR variants, or post-translational modifications. GR induces apoptosis by directly modulating the expression of genes involved in cell survival/apoptosis [18, 37], or affecting gene networks involved in stress signalling resulting in an apoptotic stimulus [36, 38].
3. GR transcriptional activity is necessary for its pro-apoptotic function
Glucocorticoid induced apoptosis depends on the presence of adequate amounts of transcriptionally active GR [34, 39, 40, 41, 42]. It has also been shown that the presence of specific GR splicing variants is necessary for the stimulation of GCs dependent apoptosis [3]. Alternative hGR splicing produces two receptor variants called GRα and GRβ, which are highly homologous differing by 50 additional amino acids present in the carboxy terminal region of GRα [43]. GRα is mainly cytoplasmic, and exhibits the typical glucocorticoid receptor function in terms of ligand-dependent transcriptional regulation and as such it is the major functional GR isoform therefore its expression is crucial for cellular sensitivity to GCs [3]. GRβ on the other hand, does not bind ligands, and exerts a dominant negative effect on GRα transcriptional activity [43, 44, 45]. In clinical studies reduced GRα protein levels correlate with resistance to GCs induced apoptosis and disadvantageous prognosis in ALL [3]. Additional indication that GR transcriptional activity is necessary for the initiation of the GCs mediated apoptosis has been provided by the observation that various mutations affecting GR transcriptional activity have been detected in patients exhibiting resistance to glucocorticoids treatment [2, 46]. Furthermore, prolonged glucocorticoid treatment significantly reduces GRα expression [47], whereas GRβ expression is not affected [48].
4. GR dependent regulation of the balance between pro- and anti-apoptotic Bcl-2 family members
B cell leukaemia/ lymphoma 2-like (Bcl-2) family members are categorised into pro- and anti-apoptotic and the balance between the levels of these two types of proteins determines the cellular fate (survival or death) [23]. The involvement of the Bcl-2 family members in the glucocorticoid-induced apoptosis has been shown in cellular and animal studies [49]. For example, the expression of the anti-apoptotic Bcl-2 family member in glucocorticoid-sensitive thymocytes is lower compared to that in glucocorticoid-resistant ones [2], and overexpression of the anti-apoptotic Bcl-2 and B-cell lymphoma-extra large (Bcl-xL) in human ALL prevents glucocorticoids induced apoptosis [50, 51, 52, 53] whereas knock down of the pro-apoptotic member Bim confers resistance to dexamethasone mediated apoptosis [54]. Furthermore, over-expression of the pro-apoptotic Bax [55] and knock down of the myeloid cell leukemia sequence 1 (Mcl-1) sensitises ALL cells to glucocorticoid treatment [56]. We have shown recently that the balance between Mcl-1 and phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) is a determinant of resistance / sensitivity of ALL cells to glucocorticoid-induced apoptosis [57, 58]. Several studies have shown that the pro-apoptotic Bcl-2 family member Bim plays crucial role in the glucocorticoid-induced apoptosis but further investigation is required to define the detailed molecular mechanisms of this process. Up-regulated Bim has been observed in various cell lines upon glucocorticoid treatment including ALL cells [59], primary chronic lymphocytic leukaemia (CLL) cells [27], and some patients with ALL [60]. Moreover knockout of Bim, p53 up-regulated modulator of apoptosis (Puma) or Noxa, or double knockouts of Bax and Bak confer resistance to glucocorticoid-mediated apoptosis in thymocytes [61, 62, 63]. Overall the balance of the levels between pro- and anti-apoptotic Bcl-2 family members has been recognised as a crucial factor in the determination of lymphocytes survival or death and induction of the glucocorticoid dependent programmed cell death.
Bcl2 | B-cell Lymphoma 2 (Bcl-2) | Anti-apoptotic | Over-expression of Bcl-2 in human ALL cells prevents glucocorticoids induced apoptosis [41, 64] |
BCL-xL | B-cell lymphoma-extra large (Bcl-xL) | Anti-apoptotic | Over-expression of Bcl-xL in human ALL cells prevents glucocorticoids induced apoptosis [23] |
BCL2L11 | BCL2 Like 11 (Bim) | Pro-apoptotic | Knock down of Bim confers resistance of ALL cells to glucocorticoid-induced apoptosis [65]. Upregulation of Bim sensitizes cells to glucocorticoid-induced apoptosis [27, 66]. |
Mcl1 | Myeloid cell leukemia 1 (Mcl-1) | Anti-apoptotic | Knock down of Mcl-1 sensitises ALL cells to glucocorticoids apoptotic effect [56]. |
Phorbol-12-myristate-13-acetate-induced protein 1 | Phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) | Pro-apoptotic | Noxa regulates the Mcl-1 protein stability and Noxa/Mcl-1 balance determines cell survival or death [57]. |
p53 up-regulated modulator of apoptosis | p53 upregulated modulator of apoptosis (Puma) | Pro-apoptotic | Puma facilitates glucocorticoid-induced apoptosis of lymphocytes [62, 65]. |
Bax | Bcl-2–associated X (Bax) | Pro-apoptotic | Bax protein regulates glucocorticoid induced apoptosis in thymocytes [67]. Double knockouts of Bax and Bak confer resistance to glucocorticoid-induced apoptosis in thymocytes [68]. |
Bak | Bcl-2 homologous antagonist/killer (Bak) | Pro-apoptotic | Double knockouts of Bax and Bak confer resistance to glucocorticoid-mediated apoptosis in thymocytes [68]. |
5. Autophagy
Autophagy is a several steps process leading to cellular degradation of unfolded or aggregated proteins and organelles in response to diverse types of stress such as starvation or metabolic stress and is an essential mechanism contributing to survival, differentiation, development, and homeostasis. Autophagy protects against chronic inflammatory conditions occurring in a variety of pathological situations such as infections, cardiovascular disease, neurodegenaration, inflammatory bowel diseases, aging and cancer [69]. Autophagy has been shown to be involved in prosurvival processes facilitating resistance of cancer cells to chemotherapy as well as under certain conditions in apoptosis [70]. Taking into account the fact that autophagy is prosurvival in addition to reports indicating that inhibitors of autophagy re-sensitise cancer cells to anticancer therapeutics [70, 71] as well as that autophagy is associated with inflammation and resistance to cancer therapy investigators were prompted to study the role of autophagy in the resistance to glucocorticoid induced apoptosis in ALL [72, 73]. These studies have indicated that dexamethasone induces autophagy before the initiation of apoptosis in ALL cells and in actual fact autophagy is a prerequisite for the efficient execution of apoptosis mediated by dexamethasone [72, 73]. More recently the molecular mechanism by which activation of autophagy overturns glucocorticoid resistance has been elucidated [74] signifying the important role of the autophagy inducer beclin-1 and the anti-apoptotic Bcl-2 family member Mcl-1 [74, 75]. Furthermore the inhibition of caspase by selective degradation of catalase and consequent generation of high concentrations of reactive oxygen species might be an alternative mechanism explaining the role of autophagy in dexamethasone induced apoptosis [76].
6. Post-translational modifications
Post-translational modifications of GR are important in regulating its transcriptional activity, protein stability, binding of GR with other transcription factors or co-modulators and subcellular localisation, and for these reasons post-translational modifications are highly relevant to glucocorticoids therapeutic efficacy [77, 78, 79, 80, 81]. GR acetylation is cell type dependent and it is suggested to suppress the receptor’s transcriptional activity by reducing its ability to bind to the Glucocorticoid Responsive Elements (GREs) present in its target genes [82], or inhibit the ability of GR to translocate into the nucleus [83]. Regulation of GR transcriptional activity also takes place through ubiquitination and proteasomal degradation of the receptor upon ligand binding [84, 85]. Ubiquitination promotes interaction of GR with E2 conjugating and E3 ligase proteins causing turnover of the receptor and thus down-regulation of its transcriptional activity [85]. In support of these conclusions the proteasome inhibitor MG-132 enhances the transcriptional activity of GR [84]. Ligand-independent sumoylation has been shown to both inhibit [86, 87] as well as to stabilise and potentiate GR transcriptional activity [88]. Three sumoylation sites have been identified within the GR protein conferring GR transcriptional target selectivity [87]. We have recently reported that GR sumoylation is assisted by its phosphorylation at particular sites under certain conditions [89].
GR phosphorylation has been extensively investigated and several different kinases have been identified to induce phosphorylation of the receptor at distinct serine and threonine residues located within the N-terminal AF-1 transactivation domain of the receptor, either in the presence or in the absence of glucocorticoid hormone [90, 91, 92, 93, 94, 95]. S203 residue in human GR is targeted by cyclin/cyclin dependent kinase (CDK) complexes and is located mostly in the cytoplasm thus it is thought to be transcriptionally inactive [89, 95]. GR phosphorylated at S211 is transcriptionally active due to conformational changes which facilitate increased recruitment of the receptor to GRE-containing promoters and is a target for phosphorylation by both cyclin/CDK kinases and MAPK families depending on the cell type [91, 96]. GR phosphorylation at S226 results in inhibition of the GR function, possibly due to increased GR nuclear export and is a result of JNK activation [80, 89, 97, 98]. Finally, phosphorylation of GR at S404 attenuates GR signalling and is due to GSK3 kinase activation [99]. We have recently reported that differential GR phosphorylation in the resistant CEM-C1-15 versus sensitive CEM-C7-14 ALL cells modulates GR transcriptional activity and target selectivity resulting in diverse pro- or anti-apoptotic Bcl-2 family members’ gene expression in the two cell lines [58]. In particular we have shown that GR phosphorylation at S211 is predominant in the glucocorticoid-sensitive CEM-C7-14 whereas GR phosphorylation at S226 by c-Jun N-terminal Kinase (JNK) occurs more frequently in the glucocorticoid-resistant CEM-C1-15 cells [58]. These observations lend support to the suggestion that different kinase pathways are responsible for GR phosphorylation in resistant versus sensitive cells to glucocorticoid induced apoptosis, thereby causing GR transcriptional inactivity in the resistant cell lines [58] concomitant Mcl-1 overexpression and hence resistance to GC treatment [56].
Apart from the differential expression of pro- and anti-apoptotic Bcl-2 family members [58] we have recently reported that GR isoforms localised in mitochondria are predominantly phosphorylated at serine 232 compared to serine 246 of the rat GR (corresponding to human GR Ser211 and Ser226 respectively) [96] possibly due to differential conformation of the two phosphoisoforms or diverse interaction patterns with components of the mitochondrial import machinery of the GR phosphorylated at serine 211 versus the GR phosphorylated at serine 226. These observations provide an additional potential explanation for the resistance of the CEM-C1-15 to glucocorticoids induced apoptosis in accord with recent reports indicating differential GR mitochondrial localisation in resistant compared to sensitive ALL cells to glucocorticoid induced apoptosis [93, 94, 95, 97].
7. Mitochondrial GR, glucocorticoids and cellular energy metabolism
Glucocorticoid hormones directly affect mitochondrial membranes inducing loss of mitochondrial transmembrane potential, thereby affecting vital cellular processes mediated by the function of this organelle such as ATP generation via oxidative phosphorylation, regulation of calcium flux and apoptosis [98]. In addition, glucocorticoids exert their effects on mitochondrial biogenesis through the mitochondrial GR [97, 99, 100, 101]. The intracellular trafficking of the glucocorticoid receptor has been shown to play important role in glucocorticoid-induced apoptosis [97, 102]. The glucocorticoid receptor translocates to mitochondria [97, 100, 101, 102], in various cells including rat brain and various other tissues’ mitochondria [99], as well as lymphoma cells [97]. GR translocation to the nucleus occurs in both glucocorticoid-sensitive and glucocorticoid-resistant cells, whereas in contrast, GR translocation into mitochondria occurs only in the glucocorticoid-sensitive and not the resistant cells [97, 103]. The mechanisms by which GR translocates to mitochondria and its effects on the regulation of the expression of mitochondrially encoded genes have been partially elucidated [97, 100, 101, 102] and require further investigation. However, it is noteworthy that glucocorticoids modulate mitochondrial biogenesis and mitochondrial energy production pathways by regulating the transcription of the mitochondrial genome [99, 100].
The process of programmed cell death is energy dependent requiring the precise coordination of several biochemical processes including the transcriptional regulation of the expression of genes encoding enzymatic components of the energy production pathways (oxidative phosphorylation (OXPHOS) and glycolysis) [29] and mutations affecting cellular energy production lead to defects in apoptosis and tumourigenesis [104, 105, 106, 107, 108, 109]. In humans the OXPHOS pathway consists of five multi-subunit complexes whose components are encoded by genes located in both the nuclear and the mitochondrial genomes [110] supporting the notion that a transcription factor operating in both subcellular compartments could coordinate the expression of nuclear and mitochondrial genes ensuring appropriate stoichiometry and timely gene expression of the components of the respiratory chain [111]. In addition to the availability of the components encoded in the nuclear and the mitochondrial compartments an appropriate assembly mechanism of these subunits is essential for the functionality of the oxidative phosphorylation system [110]. One possible candidate transcription factor able to orchestrate nuclear and mitochondrial gene expression is the glucocorticoid receptor which mediates gene expression of both nuclear and mitochondrial encoded genes [98, 99, 100, 102, 112, 113, 114, 115, 116].
In fact, dexamethasone has been shown to affect energy metabolism and the balance between OXPHOS and glycolysis [117, 118]. Also, evidence has been recently presented indicating that changes in metabolic patterns and cellular proliferation are key aspects of resistance to GC mediated apoptosis in ALL [39]. Elevated glycolytic rate due to increased expression of genes involved in glucose metabolism are associated with resistance to glucocorticoid induced apoptosis and this resistance can be reversed by inhibitors of glycolysis in ALL [119, 120]. Moreover, glucocorticoid induced apoptosis is regulated by genes involved in cellular energy metabolism [121, 122, 123, 124] suggesting that dexamethasone contributes to the apoptosis / survival decisions in ALL cells indirectly by modulating the balance between OXPHOS and glycolysis [15, 120]. Indeed coordination of oxidative phosphorylation and glycolysis by mechanisms involving glucocorticoid receptor mediated transcriptional regulation of genes encoding enzymes implicated in both pathways has been extensively reported in the literature [99, 125, 126]. Enzymes participating in the tricarboxylic acid cycle encoded by the nuclear genome such as malate dehydrogenase 1 (Mdh1) and succinyl coenzyme A synthetase (Suclg1) are GR transcriptional target genes [127]. In addition, several mitochondrial genes encoding subunits of the OXPHOS pathway possess one or more functional glucocorticoid responsive elements [99, 100, 102, 112, 113] implying that glucocorticoids exert direct effects on mitochondrial biogenesis and respiration. Key enzymes involved in glycolysis including 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase [126] lactate dehydrogenase B (LdhB) and aldolase A (AldoA) [128] are under GR transcriptional control [120].
To shed light on the molecular mechanisms involved in GR mediated regulation of the OXPHOS pathway bioinformatic analysis using the TRED or CCTFSP software [129, 130, 131] was performed to identify potential glucocorticoid responsive elements (GREs) in the promoters of genes encoding Surf-1, and SCO2 enzymes which are essential for the assembly of the Cytochrome
A marked reduction of Surf-1 mRNA levels in the resistant CEM-C1-15 cells was observed after 6 and 12 hours of dexamethasone treatment compared to the non-treated cells (Figure 2A, solid line). In contrast, in the sensitive to glucocorticoid-induced apoptosis CEM-C7-14 cells, Surf-1 mRNA levels remained constant during the first 6 hours of dexamethasone treatment and a moderate increase of Surf-1 mRNA levels was observed only 12h after the addition of the hormone (Figure 2A, dotted line). SCO-2 mRNA levels initially increased after 3h and 6h of dexamethasone treatment in CEM-C1-15 cells and later after 12h of dexamethasone treatment decreased to the level of that exhibited in the untreated cells (Figure 2B, solid line).
The fact that COX-Va expression is altered in various tumours and its association with Surf-1 in the formation of sub-complexes consisting of variable COX subunits such as COX-I, COX-II, COX-III, and COX-IV [136] triggered our interest to investigate the regulation of the expression of the COX-Va gene. This investigation aimed to test whether differential COX-Va cellular levels in the resistant versus the sensitive CEM cells in response to glucocorticoid treatment was taking place in a similar way as that observed for Surf-1. COX-Va mRNA levels were higher in CEM-C7-14 compared to those detected in the CEM-C1-15 cells in all time points of dexamethasone treatment investigated in this study and the longer the incubation with the hormone the higher the COX-Va mRNA levels in the CEM-C7-14 cells (Figure 2C, compare dotted to solid line). Results shown in Figure 2A, 2B, and 2C support the notion that the Surf-1 and COX-Va genes encoded by the nuclear genome are under GR transcriptional control and their expression is higher in the sensitive to glucocorticoid induced apoptosis cells compared to the resistant CEM-C1-15 cells.
The protein levels of Surf-1, SCO2 and COX-Va were also followed in CEM-C7-14 and CEM-C1-15 cells under the same conditions (Figure 3). Higher Surf-1 protein levels were observed in dexamethasone treated CEM-C7-14 cells compared to the non-treated cells for all time points tested (Figure 3A, B and C compare grey bars 2, 3 and 4 to grey bar 1). In contrast lower Surf-1 protein levels were observed in the dexamethasone treated CEM-C1-15 cells irrespectively of the length of the dexamethasone treatment compared to the untreated cells (Figure 3A, B and C compare black bars 2, 3 and 4 to black bar 1). In a similar manner to that observed for Surf-1, increasing SCO2 protein levels were observed in CEM-C7-14 cells treated with dexamethasone for 12h and 24h compared to the untreated cells (Figure 3A, B and D compare grey bars 2 and 3 to bar 1). On the contrary lower SCO2 protein levels were observed in CEM-C7-14 cells 36h after the addition of dexamethasone compared to the untreated cells (Figure 3A, B and D compare grey bar 4 to grey bar 1). On the other side the SCO2 protein levels in CEM-C1-15 cells were lower than those measured in the untreated cells for all the time points of dexamethasone treatment examined in this study (Figure 3A, B and D compare black bars 2, 3 and 4 to black bar 1). Finally the COX-Va protein levels were higher in both CEM-C1-15 and CEM-C7-14 cells treated with dexamethasone compared to the non-treated cells (Figure 3A, B and E compare black and grey bars 2, 3, and 4 to grey and black bars 1).
The expression of COX subunits and oxidative phosphorylation are affected by glucocorticoid treatment [137] possibly through the GR transcriptional activity. Given that some OXPHOS subunits are encoded by the nuclear genome, and others by the mitochondrial DNA, it was thought that glucocorticoids exert indirect effects on the regulation of transcription of mitochondrial encoded OXPHOS subunits by modulating the activity of nuclear factors involved in the gene expression of mitochondrial genes [101]. However, the identification of mitochondrial GR, and the existence of GRE-like domains in the mitochondrial genome [100, 101, 138] suggest that glucocorticoids exert direct effects on mitochondrial transcription. Taking into consideration the fact that glucocorticoid receptor potentially regulates the expression of several COX assembly factors and nuclear COX subunits (Figure 2A, 2B and 2C) it was interesting to investigate whether GR fine tunes the expression of OXPHOS genes in both nuclear and mitochondrial genomes. In order to assess this hypothesis, and in parallel, to strengthen the perception that energy metabolism is a possible pathway by which CEM cells determine resistance / sensitivity to glucocorticoid induced apoptosis we followed the mRNA levels of the mitochondrial OXPHOS subunits COX-I, COX-II and COX-III in CEM C1-15 and CEM C7-14 cells treated with dexamethasone (Figures 4A, 4B and 4C).
A similar picture to that observed for the nuclear OXPHOS components was observed for the mitochondrial OXPHOS subunits. Specifically higher cellular levels of the mitochondrial COX-I, COX-II and COX-III OXPHOS subunits were observed in CEM-C7-14 compared to CEM-C1-15 cells (Figure 4A-4C). Increased levels of COX-I mRNA in both cell lines after 12 hours of dexamethasone treatment were observed in both CEM-C1-15 and CEM-C7-14 cells (Figure 4A, compare solid with dotted line). COX-II mRNA expression initially decreased in both cell lines 3h after the addition of dexamethasone (Figure 4B, compare solid and dotted lines 3h point) and then started to increase steadily at 6 and 12h after the treatment with the hormone but it reached higher levels in the CEM-C7-14 cells (Figure 4B, compare solid line with dotted line). COX-III gene expression remains unaffected by glucocorticoid treatment during the first 3 hours, in CEM-C1-15 cells, followed by two fold increase 6h and 12h after hormone addition (Figure 4C, solid line compare 0 time point with 6 and 12h time points). A similar pattern was evident in CEM-C7-14 cells where the induction of COX-III mRNA after 6h and 12h of dexamethasone treatment was four and five fold higher respectively compared to those detected in the untreated cells (Figure 4C, dotted line compare 0 time point with 6 and 12h time points).
Taken together, results presented in this manuscript endorse the hypothesis that the glucocorticoid resistance / sensitivity in CEM cells is determined by differences in the efficacy of the OXPHOS system to produce energy in the two cell lines. Support to this conclusion is lent by observations shown in Figure 2A, 2B and 2C indicating that the mRNA levels of nuclear encoded components of the OXPHOS system were higher in the sensitive CEM-C7-14 than in the resistant CEM-C1-15 cells. Higher levels of COX assembly factors in CEM-C7-14 cells imply a more efficient energy metabolism in these cells. This could be a result of distinct signalling pathways operating in the two cell lines giving rise to increased transactivation function of GR in CEM-C7-14 cells, where the receptor could be phosphorylated at S211 [58] and stimulate the expression of its potential transcription targets Surf-1 and COX-Va, whereas on the contrary, it is phosphorylated at S226 in CEM-C1-15 cells, thereby targeted to different subset of its transcriptional targets in these cells [58]. The link between altered metabolism in cancer cells and varying expression of COX subunits has been well established [139, 140, 141]. The presence of mitochondrial GR and of GRE-like domains in the mitochondrial genome [100, 102, 138, 142, 143, 144] and regulation of the mitochondrial COX subunits (COX-I, COX-II and COX-III) provide a probable mechanism explaining the dexamethasone dependent regulation of the mitochondrial COX subunits gene expression (Figure 4). In addition, differences in post translational modifications of the receptor, which in the case of CEM-C7-14 cells, allow activation [58] and possibly translocation of GR into mitochondria [96] while in CEM-C1-15 cells these events are not permissible could be an additional justification for these observations.
8. Conclusions and future perspectives
Resistance to glucocorticoid induced apoptosis in ALL has been attributed to several different processes and pathways including predominance of certain GR isoforms with reduced transcriptional activity [34, 145, 146], either due to altered binding capacity of the receptor to other transcription factors [147, 148, 149, 150] or co-regulators [81, 151], disparate expression and consequent dissimilar balance between pro- versus anti-apoptotic members of the Bcl-2 family [18], GR mitochondrial localisation [97], autophagy [72, 73, 74, 75], and post-translational modifications which affect GR transcription target selectivity and protein stability [22, 38, 89, 152, 153].
We have recently presented evidence to suggest that differential GR phosphorylation in resistant versus sensitive to glucocorticoid induced apoptosis ALL cells results in selective induction of anti-apoptotic and inhibition of pro-apoptotic Bcl-2 family members gene expression in the resistant cells [58]. Several reports have indicated the potential role of differential kinase activity in glucocorticoid resistant and sensitive cells in determining the GR subcellular localisation [96, 98, 154] and diverse effects on the induction of autophagy [72, 73, 74].
In this study we provide new evidence signifying the differential expression of OXPHOS components in glucocorticoid resistant versus sensitive ALL cells and we propose that resistant and sensitive CEM cells use different pathways to produce energy. These results are in accord with reports showing that resistance to GC in ALL is associated with increased glucose consumption [155] with concomitant induction of Mcl-1 expression and resistance to apoptosis [39]. In our anticipated model (Figure 5) in resistant lymphocytes the predominantly phosphorylated at S226 GR is possibly transcriptionally inactive and thus incapable to significantly induce OXPHOS assembly enzymes and COX subunits gene expression or translocate into mitochondria thereby exhibiting reduced oxidative phosphorylation consistent with a proliferative phenotype, and this is probably one of the mechanisms employed by the glucocorticoid-resistant CEM-C1-15 cells to survive GC treatment.
The results presented in this study endorse the hypothesis that differential GR phosphorylation affects components of cellular energy production pathways in distinct ways in resistant versus sensitive cells altering energy production and possibly ROS generation in unique ways in the two cell lines, suggesting that combination of kinase inhibitors, and glycolytic modulators together with dexamethasone could be a possible mean by which resistance to glucocorticoid induced apoptosis could be circumvented in ALL.
References
- 1.
Buttgereit F. Saag K. G. Cutolo M. da Silva. J. A. P. Bijlsma J. W. J. 2005 The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis Scand J Rheumatol34 14 21 - 2.
Sionov R. V. Spokoini R. Kfir-Erenfeld S. Cohen O. Yefenof E. 2008 Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis Adv Cancer Res101 127 248 - 3.
Schmidt S. Rainer J. Ploner C. Presul E. Riml S. et al. 2004 Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11 Suppl 1: S45 55 - 4.
Losel R. Wehling M. 2003 Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol4 46 56 - 5.
Buttgereit F. Straub R. H. Wehling M. Burmester G. R. 2004 Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum50 3408 3417 - 6.
Stellato C. 2004 Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc1 255 263 - 7.
Solito E. Mulla A. Morris J. F. Christian H. C. Flower R. J. et al. 2003 Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. 144 1164 1174 - 8.
Qiu J. Wang C. G. Huang X. Y. Chen Y. Z. 2003 Nongenomic mechanism of glucocorticoid inhibition of bradykinin-induced calcium influx in PC12 cells: possible involvement of protein kinase C. Life Sci72 2533 2542 - 9.
Long F. Wang Y. X. Liu L. Zhou J. Cui R. Y. et al. 2005 Rapid nongenomic inhibitory effects of glucocorticoids on phagocytosis and superoxide anion production by macrophages. 70 55 61 - 10.
Liu L. Wang Y. X. Zhou J. Long F. Sun H. W. et al. 2005 Rapid non-genomic inhibitory effects of glucocorticoids on human neutrophil degranulation. Inflamm Res54 37 41 - 11.
Koukouritaki S. B. Gravanis A. Stournaras C. 1999 Tyrosine phosphorylation of focal adhesion kinase and paxillin regulates the signaling mechanism of the rapid nongenomic action of dexamethasone on actin cytoskeleton. Mol Med5 731 742 - 12.
Löwenberg M. Stahn C. Hommes D. W. Buttgereit F. 2008 Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands 73 1025 1029 - 13.
Smith LK, Cidlowski JA 2010 Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes Prog Brain Res182 1 30 - 14.
Frankfurt O. Rosen S. T. 2004 Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol16 553 563 - 15.
Distelhorst CW 2002 Recent insights into the mechanism of glucocorticosteroid-induced apoptosis Cell Death Differ9 6 19 - 16.
Lepine S. Sulpice J. C. Giraud F. 2005 Signaling pathways involved in glucocorticoid-induced apoptosis of thymocytes. Crit Rev Immunol25 263 288 - 17.
Thorburn A. 2004 Death receptor-induced cell killing. Cell Signal16 139 144 - 18.
Ploner C. Schmidt S. Presul E. Renner K. Schrocksnadel K. et al. 2005 Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol93 153 160 - 19.
D’Adamio F. Zollo O. Moraca R. Ayroldi E. Bruscoli S. et al. 1997 A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. 7 803 812 - 20.
Ashwell JD, Lu FW, Vacchio MS 2000 Glucocorticoids in T cell development and function. Annu Rev Immunol18 309 345 - 21.
Planey S. L. Abrams M. T. Robertson N. M. Litwack G. 2003 Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells. Cancer Res63 172 178 - 22.
Garza AS, Miller AL, Johnson BH, Thompson EB 2009 Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions Leuk Res33 717 727 - 23.
Almawi WY, Melemedjian OK, Jaoude MM 2004 On the link between Bcl-2 family proteins and glucocorticoid-induced apoptosis. J Leukoc Biol76 7 14 - 24.
Bouillet P. Metcalf D. Huang D. C. Tarlinton D. M. Kay T. W. et al. 1999 Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science286 1735 1738 - 25.
Shi Y. 2004 Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci13 1979 1987 - 26.
Abrams M. T. Robertson N. M. Yoon K. Wickstrom E. 2004 Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem279 55809 55817 - 27.
Iglesias-Serret D. de Frias M. Santidrian A. F. Coll-Mulet L. Cosialls A. M. et al. 2007 Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia21 281 287 - 28.
Wang Z. Malone M. H. He H. Mc Coll K. S. Distelhorst C. W. 2003 Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem278 23861 23867 - 29.
Elmore S. 2007 Apoptosis: a review of programmed cell death Toxicol Pathol35 495 516 - 30.
Lauber K. Appel H. A. Schlosser S. F. Gregor M. Schulze-Osthoff K. et al. 2001 The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. J Biol Chem276 29772 29781 - 31.
Arai Y. Nakamura Y. Inoue F. Yamamoto K. Saito K. et al. 2000 Glucocorticoid-induced apoptotic pathways in eosinophils: comparison with glucocorticoid-sensitive leukemia cells. Int J Hematol71 340 349 - 32.
Segal M. Niazi S. Simons M. P. Galati S. A. Zangrilli J. G. 2007 Bid activation during induction of extrinsic and intrinsic apoptosis in eosinophils. Immunol Cell Biol85 518 524 - 33.
Kaufmann T. Tai L. Ekert P. G. Huang D. C. Norris F. et al. 2007 The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell129 423 433 - 34.
Oakley RH, Cidlowski JA 2011 Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids J Biol Chem286 3177 3184 - 35.
Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science240 889 895 - 36.
Yamamoto KR 1985 Steroid receptor regulated transcription of specific genes and gene networks. Annu Rev Genet19 209 252 - 37.
Ploner C. Rainer J. Niederegger H. Eduardoff M. Villunger A. et al. 2008 The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia 22 370 377 - 38.
Kfir-Erenfeld S. Sionov R. V. Spokoini R. Cohen O. Yefenof E. 2010 Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations Leuk Lymphoma51 1968 2005 - 39.
Beesley A. H. Weller R. E. Senanayake S. Welch M. Kees U. R. 2009 Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines Leuk Res33 321 325 - 40.
Medh R. D. MS Webb Miller. A. L. Johnson B. H. Fofanov Y. et al. 2003 Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. 81 543 555 - 41.
Herold MJ, McPherson KG, Reichardt HM 2006 Glucocorticoids in T cell apoptosis and function Cell Mol Life Sci63 60 72 - 42.
Helmberg A. Auphan N. Caelles C. Karin M. 1995 Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J14 452 460 - 43.
Zhou J. Cidlowski J. A. 2005 The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. 70 407 417 - 44.
Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA 1999 The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem274 27857 27866 - 45.
Kino T. Liou S. H. Charmandari E. Chrousos G. P. 2004 Glucocorticoid receptor mutants demonstrate increased motility inside the nucleus of living cells: time of fluorescence recovery after photobleaching (FRAP) is an integrated measure of receptor function. Mol Med10 80 88 - 46.
Hillmann A. G. Ramdas J. Multanen K. Norman M. R. Harmon J. M. 2000 Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res60 2056 2062 - 47.
Zilberman Y. Zafrir E. Ovadia H. Yefenof E. Guy R. et al. 2004 The glucocorticoid receptor mediates the thymic epithelial cell-induced apoptosis of CD4+8+ thymic lymphoma cells. Cell Immunol227 12 23 - 48.
Webster JC, Oakley RH, Jewell CM, Cidlowski JA 2001 Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci U S A98 6865 6870 - 49.
Youle R. J. Strasser A. 2008 The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol9 47 59 - 50.
Hartmann B. L. Geley S. Loffler M. Hattmannstorfer R. Strasser-Wozak E. M. et al. 1999 Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. 18 713 719 - 51.
Broome H. E. Yu A. L. Diccianni M. BM Camitta Monia. B. P. et al. 2002 Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leuk Res26 311 316 - 52.
Bailly-Maitre B. de Sousa G. Boulukos K. Gugenheim J. Rahmani R. 2001 Dexamethasone inhibits spontaneous apoptosis in primary cultures of human and rat hepatocytes via Bcl-2 and Bcl-xL induction Cell Death Differ8 279 288 - 53.
Huang ST, Cidlowski JA 2002 Phosphorylation status modulates Bcl-2 function during glucocorticoid-induced apoptosis in T lymphocytes. FASEB J16 825 832 - 54.
Lu J. Quearry B. Harada H. 2006 FEBS Lett 580: 3539-3544.38 kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells - 55.
Salomons G. S. Brady H. J. M. Verwijs-Janssen M. Van Den Berg. JD Hart A. A. M. et al. 1997 The Baxα:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer71 959 965 - 56.
Wei G. Twomey D. Lamb J. Schlis K. Agarwal J. et al. 2006 Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance 10 331 342 - 57.
Alves N. L. Derks I. A. Berk E. Spijker R. van Lier R. A. et al. 2006 The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells 24 703 716 - 58.
Lynch J. T. Rajendran R. Xenaki G. Berrou I. Demonacos C. et al. 2010 The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. Mol Cancer 9:38 EOF - 59.
Jiang N. Koh G. S. Lim J. Y. Kham S. K. Ariffin H. et al. 2011 BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia Exp Hematol39 321 329 - 60.
Schmidt S. Rainer J. Riml S. Ploner C. Jesacher S. et al. 2006 Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. 107 2061 2069 - 61.
Bouillet P. Metcalf D. Huang D. C. S. Tarlinton D. M. Kay T. W. H. et al. 1999 Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. Science286 1735 1738 - 62.
Villunger A. Michalak E. M. Coultas L. Mullauer F. Bock G. et al. 2003 Science 302: 1036-1038.53 drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. - 63.
Herr I. Gassler N. Friess H. Büchler M. 2007 Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids 12 271 291 - 64.
Memon S. A. Moreno M. B. Petrak D. Zacharchuk C. M. 1995 Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma. J Immunol155 4644 4652 - 65.
Erlacher M. Michalak E. M. Kelly P. N. Labi V. Niederegger H. et al. 2005 BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. 106 4131 4138 - 66.
Real P. J. Tosello V. Palomero T. Castillo M. Hernando E. et al. 2009 Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med15 50 58 - 67.
Hoijman E. Rocha Viegas. L. Keller Sarmiento. M. I. Rosenstein R. E. Pecci A. 2004 Involvement of Bax protein in the prevention of glucocorticoid-induced thymocytes apoptosis by melatonin. 145 418 425 - 68.
Rathmell J. C. Lindsten T. Zong W. X. Cinalli R. M. Thompson C. B. 2002 Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol3 932 939 - 69.
Fésüs L. Demény M. Á. Petrovski G. 2011 Autophagy shapes inflammation Antioxid Redox Signal14 2233 2243 - 70.
Mizushima N. 2007 Autophagy: process and function. Genes Dev21 2861 2873 - 71.
Chen S. Rehman S. K. Zhang W. Wen A. Yao L. et al. 2010 Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta1806 220 229 - 72.
Grander D. Kharaziha P. Laane E. Pokrovskaja K. Panaretakis T. 2009 Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies 5 1198 1200 - 73.
Laane E. Tamm K. P. Buentke E. Ito K. Khahariza P. et al. 2009 Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy Cell Death Differ16 1018 1029 - 74.
Bonapace L. Bornhauser B. C. Schmitz M. Cario G. Ziegler U. et al. 2010 Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance J Clin Invest120 1310 1323 - 75.
Heidari N. MA Hicks Harada. H. 2010 GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 1:e76 EOF - 76.
Yu L. Wan F. Dutta S. Welsh S. Liu Z. et al. 2006 Autophagic programmed cell death by selective catalase degradation Proc Natl Acad Sci U S A103 4952 4957 - 77.
Luecke HF, Yamamoto KR 2005 The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev19 1116 1127 - 78.
De Bosscher K. Vanden Berghe. W. Haegeman G. 2000 Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol109 16 22 - 79.
Nawata H. Okabe T. Yanase T. Nomura M. 2008 Mechanism of action and resistance to glucocorticoid and selective glucocorticoid receptor modulator to overcome glucocorticoid-related adverse effects Clinical & Experimental Allergy Reviews8 53 56 - 80.
Perissi V. Rosenfeld M. G. 2005 Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol6 542 554 - 81.
Davies L. Paraskevopoulou E. Sadeq M. Symeou C. Pantelidou C. et al. 2011 Regulation of glucocorticoid receptor activity by a stress responsive transcriptional cofactor. Mol Endocrinol25 58 71 - 82.
Nader N. Chrousos G. P. Kino T. 2009 Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications FASEB J23 1572 1583 - 83.
Matthews J. G. Ito K. Barnes P. J. Adcock I. M. 2004 Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol113 1100 1108 - 84.
Wallace AD, Cidlowski JA 2001 Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem276 42714 42721 - 85.
Deroo B. J. Rentsch C. Sampath S. Young J. De Franco D. B. et al. 2002 Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking Mol Cell Biol22 4113 4123 - 86.
Holmstrom S. ME Van Antwerp-Lluhi Iniguez. J. A. 2003 Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy Proc Natl Acad Sci U S A100 15758 15763 - 87.
Tian S. Poukka H. Palvimo J. J. Janne O. A. 2002 Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochem J367 907 911 - 88.
Le Drean Y. Mincheneau N. Le Goff P. Michel D. 2002 Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. 143 3482 3489 - 89.
Davies L. Karthikeyan N. Lynch J. T. Sial E. A. Gkourtsa A. et al. 2008 Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function Mol Endocrinol22 1331 1344 - 90.
MD Krstic Rogatsky. I. Yamamoto K. R. MJ Garabedian 1997 Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol17 3947 3954 - 91.
Hoeck W. Groner B. 1990 Hormone-dependent phosphorylation of the glucocorticoid receptor occurs mainly in the amino-terminal transactivation domain. J Biol Chem265 5403 5408 - 92.
Ismaili N. MJ Garabedian 2004 Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci1024 86 101 - 93.
Beck I. M. Vanden Berghe. W. Vermeulen L. Yamamoto K. R. Haegeman G. et al. 2009 Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases Endocr Rev30 830 882 - 94.
Galliher-Beckley AJ, Cidlowski JA 2009 Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease 61 979 986 - 95.
Galliher-Beckley AJ, Williams JG, Cidlowski JA 2011 Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling Mol Cell Biol31 4663 4675 - 96.
Adzic M. Djordjevic A. Demonacos C. Krstic-Demonacos M. Radojcic M. B. 2009 The role of phosphorylated glucocorticoid receptor in mitochondrial functions and apoptotic signalling in brain tissue of stressed Wistar rats Int J Biochem Cell Biol41 2181 2188 - 97.
Sionov R. V. Cohen O. Kfir S. Zilberman Y. Yefenof E. 2006 Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med203 189 201 - 98.
Hock M. B. Kralli A. 2009 Transcriptional Control of Mitochondrial Biogenesis and Function. Ann Rev Physiol. Palo Alto: Annual Reviews.177 203 - 99.
Scheller K. CE Sekeris 2003 The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation Exp Physiol88 129 140 - 100.
Demonacos C. V. Karayanni N. Hatzoglou E. Tsiriyiotis C. Spandidos D. A. et al. 1996 Mitochondrial genes as sites of primary action of steroid hormones. 61 226 232 - 101.
Demonacos C. Tsawdaroglou N. C. Djordjevic-Markovic R. Papalopoulou M. Galanopoulos V. et al. 1993 Import of the glucocorticoid receptor into rat liver mitochondria in vivo and in vitro. J Steroid Biochem Mol Biol46 401 413 - 102.
Demonacos C. Djordjevic-Markovic R. Tsawdaroglou N. CE Sekeris 1995 The mitochondrion as a primary site of action of glucocorticoids: the interaction of the glucocorticoid receptor with mitochondrial DNA sequences showing partial similarity to the nuclear glucocorticoid responsive elements. J Steroid Biochem Mol Biol55 43 55 - 103.
Sionov R. V. Kfir S. Zafrir E. Cohen O. Zilberman Y. et al. 2006 Glucocorticoid-induced apoptosis revisited: a novel role for glucocorticoid receptor translocation to the mitochondria. Cell Cycle5 1017 1026 - 104.
Kondoh H. ME Lleonart Gil. J. Wang J. Degan P. et al. 2005 Glycolytic enzymes can modulate cellular life span. Cancer Res65 177 185 - 105.
Kwong J. Q. MS Henning Starkov. AA Manfredi G. 2007 The mitochondrial respiratory chain is a modulator of apoptosis J Cell Biol179 1163 1177 - 106.
Cuezva J. M. Krajewska M. de Heredia M. L. Krajewski S. Santamaria G. et al. 2002 The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res62 6674 6681 - 107.
Lemarie A. Grimm S. 2011 Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer? Oncogene30 3985 4003 - 108.
Tomiyama A. Serizawa S. Tachibana K. Sakurada K. Samejima H. et al. 2006 Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst98 1462 1473 - 109.
Huang G. Chen Y. Lu H. Cao X. 2007 Coupling mitochondrial respiratory chain to cell death: an essential role of mitochondrial complex I in the interferon-[beta] and retinoic acid-induced cancer cell deat h. Cell Death Differ14 327 337 - 110.
Coenen MJ, van den Heuvel LP, Smeitink JA 2001 Mitochondrial oxidative phosphorylation system assembly in man: recent achievements. Curr Opin Neurol14 777 781 - 111.
Fontanesi F. Soto I. C. Horn D. Barrientos A. 2006 Assembly of mitochondrial cytochrome c-oxidase, a complicated and highly regulated cellular process Am J Physiol Cell Physiol 291: C1129 C1147. - 112.
Weber K. Brück P. Mikes Z. Küpper-H J. Klingenspor M. et al. 2002 Glucocorticoid hormone stimulates mitochondrial biogenesis specifically in skeletal muscle. 143 177 184 - 113.
Van Itallie CM 1992 Dexamethasone treatment increases mitochondrial RNA synthesis in a rat hepatoma cell line. 130 567 576 - 114.
Kulinsky V. Kolesnichenko L. 2007 Regulation of metabolic and energetic functions of mitochondria by hormones and signal transduction systems Biochemistry (Moscow) Supplemental Series B: Biomedical Chemistry1 95 113 - 115.
Ritz P. Dumas J. F. Ducluzeau P. H. Simard G. 2005 Hormonal regulation of mitochondrial energy production. Curr Opin Clin Nutr Metab Care8 415 418 - 116.
Vijayasarathy C. Biunno I. Lenka N. Yang M. Basu A. et al. 1998 Variations in the subunit content and catalytic activity of the cytochrome c oxidase complex from different tissues and different cardiac compartments Biochim Biophys Acta1371 71 82 - 117.
Martens ME, Peterson PL, Lee CP 1991 In vitro effects of glucocorticoid on mitochondrial energy metabolism. Biochim Biophys Acta1058 152 160 - 118.
Pandya JD, Agarwal NA, Katyare SS 2007 Dexamethasone treatment differentially affects the oxidative energy metabolism of rat brain mitochondria in developing and adult animals Int J Dev Neurosci25 309 316 - 119.
Holleman A. den Boer. M. L. Kazemier K. M. Janka-Schaub G. E. Pieters R. 2003 Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. 102 4541 4546 - 120.
Hulleman E. Kazemier K. M. Holleman A. Vander Weele. D. J. Rudin C. M. et al. 2009 Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells 113 2014 2021 - 121.
Adebodun F. 1999 Phospholipid metabolism and resistance to glucocorticoid-induced apoptosis in a human leukemic cell line: a 31P-NMR study using a phosphonium analog of choline Cancer Lett140 189 194 - 122.
Brown G. C. Borutaite V. 2008 Regulation of apoptosis by the redox state of cytochrome c Biochim Biophys Acta1777 877 881 - 123.
Carlet M. Janjetovic K. Rainer J. Schmidt S. Panzer-Grumayer R. et al. 2010 Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells BMC Cancer 10: 638. - 124.
Dong H. Zitt C. Auriga C. Hatzelmann A. Epstein P. M. 2010 Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells Biochem Pharmacol79 321 329 - 125.
Vander Kooi. B. T. Onuma H. Oeser J. K. CA Svitek Allen. S. R. et al. 2005 The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol19 3001 3022 - 126.
Lange A. J. Espinet C. Hall R. El -Maghrabi M. R. Vargas A. M. et al. 1992 Regulation of gene expression of rat skeletal muscle/liver 6- phosphofructo-2-kinase/fructose-2, 6-bisphosphatase: Isolation and characterization of a glucocorticoid response element in the first intron of the gen e. J Biol Chem267 15673 15680 - 127.
Datson N. A. Van Der Perk J. De Kloet E. R. Vreugdenhil E. 2001 Identification of corticosteroid-responsive genes in rat hippocampus using serial analysis of gene expression. Eur J Neurosci14 675 689 - 128.
Datson NA, Morsink MC, Meijer OC, de Kloet ER 2008 Central corticosteroid actions: Search for gene targets. Eur J Pharmacol583 272 289 - 129.
Zhao F. Xuan Z. Liu L. Zhang M. Q. 2005 TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies Nucleic Acids Res 33: D103 107 - 130.
Marinescu V. D. Kohane I. S. Riva A. 2005 MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes BMC Bioinformatics 6: 79. - 131.
Kolchanov NA, Merkulova TI, Ignatieva EV, Ananko EA, Oshchepkov DY, et al. 2007 Combined experimental and computational approaches to study the regulatory elements in eukaryotic genes Brief Bioinform8 266 274 - 132.
Yang H. Brosel S. Acin-Perez R. Slavkovich V. Nishino I. et al. 2010 Analysis of mouse models of cytochrome c oxidase deficiency owing to mutations in Sco2 Hum Mol Genet19 170 180 - 133.
Fontanesi F. Soto I. C. Horn D. Barrientos A. 2006 Assembly of mitochondrial cytochrome c-oxidase, a complicated and highly regulated cellular process Am J Physiol Cell Physiol 291: C1129 1147 - 134.
Fernandez-Vizarra E. Tiranti V. Zeviani M. 2009 Assembly of the oxidative phosphorylation system in humans: what we have learned by studying its defects. Biochim Biophys Acta1793 200 211 - 135.
Harmon JM, Thompson EB 1981 Isolation and characterization of dexamethasone-resistant mutants from human lymphoid cell line CEM-C7. Mol Cell Biol1 512 521 - 136.
Williams S. L. Valnot I. Rustin P. Taanman J. W. 2004 Cytochrome c oxidase subassemblies in fibroblast cultures from patients carrying mutations in COX10, SCO1, or SURF1. J Biol Chem279 7462 7469 - 137.
Rachamim N. Latter H. Malinin N. Asher C. Wald H. et al. 1995 Dexamethasone enhances expression of mitochondrial oxidative phosphorylation genes in rat distal colon. Am J Physiol 269: C1305 C1310. - 138.
Sekeris CE 1990 The mitochondrial genome: a possible primary site of action of steroid hormones. In Vivo4 317 320 - 139.
Herrmann J. M. Funes S. 2005 Biogenesis of cytochrome oxidase-sophisticated assembly lines in the mitochondrial inner membrane. 354 43 52 - 140.
Krieg R. C. Knuechel R. Schiffmann E. Liotta L. A. Petricoin E. F. et al. 2004 Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. 4 2789 2795 - 141.
Grandjean F. Bremaud L. Robert J. Ratinaud M. H. 2002 Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells. Biochem Pharmacol63 823 831 - 142.
Scheller K. CE Sekeris 2003 The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation Exp Physiol88 129 140 - 143.
Chen J. Q. Eshete M. Alworth W. L. JD Yager 2004 Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors α and β to human mitochondrial dna estrogen response elements. J Cell Biochem93 358 373 - 144.
Chen J. Q. Eshete M. Alworth W. L. JD Yager 2004 Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J Cell Biochem93 358 373 - 145.
Pujols L. Xaubet A. Ramirez J. Mullol J. Roca-Ferrer J. et al. 2004 Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases. 59 687 693 - 146.
Rainer J. Lelong J. Bindreither D. Mantinger C. Ploner C. et al. 2012 Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia Mol Endocrinol26 178 193 - 147.
De Bosscher K. Vanden Berghe. W. Haegeman G. 2003 The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev24 488 522 - 148.
Ma Xie J. Shi Y. Qin Y. Zhao W. et B. al 2008 Glucocorticoid-induced apoptosis requires FOXO3A activity. Biochem Biophys Res Commun377 894 898 - 149.
Nicholson L. Hall A. G. CP Redfern Irving. J. 2010 NFkappaB modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia. Leuk Res34 1366 1373 - 150.
Tissing W. J. Meijerink J. P. den Boer. M. L. Pieters R. 2003 Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia17 17 25 - 151.
Sivils JC, Storer CL, Galigniana MD, Cox MB 2011 Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52) Curr Opin Pharmacol11 314 319 - 152.
Chen W. Dang T. Blind R. D. Wang Z. Cavasotto C. N. et al. 2008 Glucocorticoid receptor phosphorylation differentially affects target gene expression Mol Endocrinol22 1754 1766 - 153.
Miller A. L. MS Webb Copik. A. J. Wang Y. Johnson B. H. et al. 2005 Mol Endocrinol 19: 1569-1583.38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. - 154.
Itoh M. Adachi M. Yasui H. Takekawa M. Tanaka H. et al. 2002 Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol16 2382 2392 - 155.
Bhadri VA, Trahair TN, Lock RB 2011 Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia J Paediatr Child Health.